| Name | Title | Contact Details |
|---|
Contraline, Inc. is a venture-backed medical device company devoted to providing men and couples with long-lasting, safe, and effective contraception. The company is developing ADAM™, the world`s first injectable hydrogel designed to provide long-lasting barrier contraception for men. The company was founded in 2015 by Kevin Eisenfrats and Dr. John Herr, and is headquartered in Charlottesville, Virginia.
Headquartered in Tempe, Arizona, Harvest Health & Recreation Inc. is a vertically integrated cannabis company and multi-state operator (MSO). Since 2011, Harvest has been committed to expanding its retail and wholesale presence throughout the U.S., acquiring, manufacturing, and selling cannabis products for patients and consumers in addition to providing services to retail dispensaries. Through organic license wins, service agreements, and targeted acquisitions, Harvest has assembled an operational footprint with cultivation, manufacturing and retail locations spanning multiple states in the U.S. Harvest`s mission is to improve lives through the goodness of cannabis.
Cardiac Insight, Inc. is a privately held medical device company based in Seattle, WA. Cardiac Insight is developing advanced, body worn ECG sensing technology aimed at the early diagnosis of atrial fibrillation (AF) and other conditions. Earlier last year, the company announced a strategic collaboration with Welch Allyn, now part of the Hill-Rom family of companies, for the distribution rights of certain products and technologies offered by Cardiac Insight.
Jarvik Heart is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
A publicly traded (OTC: CBSC) company providing innovative products and services in the ambulatory non-invasive cardiac monitoring space. CB Scientific, Inc., through its US and international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, provide improved compliance for patients at risk of abnormal heart rhythms as well as more accurate information for physicians.